Investigating how specific immune cells respond to cancer
Novel TCR transgenic mice to study tumor neoantigen-specific T cell responses
This study is looking at how a special type of immune cell called CD8+ T cells reacts to cancer and aims to find better ways to help these cells fight tumors, which could lead to improved treatments for patients with cancer.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10991703 on NIH RePORTER |
What this research studies
This research focuses on understanding how activated CD8+ T cells, a type of immune cell, respond to cancer-specific antigens. By using specially designed mice that express these antigens, researchers aim to uncover how these T cells can be effectively primed and recruited to fight tumors. The study will explore the mechanisms behind T cell dysfunction in the tumor environment and how these insights can improve cancer therapies, including CAR-T cell treatments. Patients may benefit from advancements in targeted immunotherapies based on the findings.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers that express specific neoantigens, particularly those who may benefit from immunotherapy.
Not a fit: Patients with cancers that do not express the targeted neoantigens or those who are not eligible for immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that harness the body's immune response to target tumors.
How similar studies have performed: Previous research using TCR transgenic mice has shown promise in understanding T cell responses to tumors, indicating that this approach has potential for success.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Kane, Lawrence P. — University of Pittsburgh at Pittsburgh
- Study coordinator: Kane, Lawrence P.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.